| 18.9857 0.426 (2.29%) | 01-26 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.57  |
1-year : | 27.53 |
| Resists | First : | 20.18 |
Second : | 23.57 |
| Pivot price | 18.66 |
|||
| Supports | First : | 18.2 |
Second : | 16.97 |
| MAs | MA(5) : | 18.84 |
MA(20) : | 18.73 |
| MA(100) : | 13.96 |
MA(250) : | 12.98 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 63.2 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 22.5 | Low : | 8.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NRIX ] has closed below upper band by 35.6%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.59 - 19.7 | 19.7 - 19.78 |
| Low: | 18.31 - 18.43 | 18.43 - 18.52 |
| Close: | 18.37 - 18.57 | 18.57 - 18.73 |
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Wed, 21 Jan 2026
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Tue, 20 Jan 2026
Nurix Therapeutics (NRIX) to Release Earnings on Tuesday - MarketBeat
Fri, 16 Jan 2026
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha
Mon, 12 Jan 2026
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha
Thu, 08 Jan 2026
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 7.144e+007 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 14,490 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.5936e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -292.5 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 157.6 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 8.369e+007 % |
| Gross Profit (p.s.) | -19.33 |
| Sales Per Share | -33.87 |
| EBITDA (p.s.) | -1.12653e+008 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -230 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.57 |
| Price to Cash Flow | 7.57 |
| Dividend | 0 |
| Forward Dividend | 1.464e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|